GLP-1 drugs are not dosed on one scale: 2.4 mg is the full maintenance dose of semaglutide, but 2.5 mg is only the starting dose of tirzepatide, and liraglutide is injected every day instead of every week. That is why a GLP-1 dosage chart has to be read drug by drug. Below: start doses, steps and maintenance doses for the main GLP-1 drugs side by side, what each achieved in its main trial, and how many syringe units those doses are.

Open the calculators → semaglutide, tirzepatide, retatrutide and more, for any vial.

GLP-1 dosage chart: all drugs side by side

DrugHow oftenStartStepsMaintenanceAverage weight loss in main trialStatus (US)
Semaglutide (Wegovy)weekly0.25 mgevery 4 weeks: 0.5 → 1 → 1.7 → 2.4 mg1.7 or 2.4 mg; 7.2 mg (Wegovy HD)−14.9% (2.4 mg, 68 wk); −18.7% (7.2 mg, 72 wk)Approved
Tirzepatide (Zepbound)weekly2.5 mg+2.5 mg after at least 4 weeks5, 10 or 15 mg−20.9% (15 mg, 72 wk)Approved
Liraglutide (Saxenda)daily0.6 mg+0.6 mg every week3 mg−8.0% (3 mg, 56 wk)Approved, generic
Retatrutideweekly2 mgevery 4 weeks: 4 → 6 → 9 → 12 mg4, 9 or 12 mg−28.3% (12 mg, 80 wk)*Not approved; filing Q1 2027
Mazdutideweekly2 mg+2 mg every 4 weeks4 or 6 mg−14.8% (6 mg, 48 wk)Approved in China only
Survodutideweeklylow, gradualgradual over several weeks3.6 or 6 mgup to −16.6% (76 wk)*Not approved
CagriSema (cagrilintide + semaglutide)weekly—stepwise2.4 + 2.4 mg−20.4% (68 wk)Not approved

Weight loss is the average in each drug’s main Phase 3 trial versus placebo, and trials differ in length and population, so the numbers are a rough guide, not a head-to-head ranking. * Average if people stayed on treatment; counting everyone, retatrutide 12 mg gave −25.0%. Wegovy HD (7.2 mg) is approved in the US for people who have tolerated 2.4 mg for at least 4 weeks.

Why the same mg is not the same dose

Each molecule has its own strength per milligram. Switching from semaglutide 2.4 mg to tirzepatide does not mean injecting 2.4 mg of tirzepatide; people who switch normally restart from the new drug’s own schedule, as decided by their prescriber. The same goes for mixing up liraglutide and semaglutide: 3 mg of liraglutide a day is a normal dose, while 3 mg of semaglutide a week is above the standard 2.4 mg maintenance dose.

Maintenance doses in syringe units

Rule: units = mg ÷ mg/mL × 100 on a U-100 insulin syringe. Common compounded and research strengths:

Maintenance doseUnits at 2.5 mg/mLUnits at 5 mg/mLUnits at 10 mg/mLUnits at 20 mg/mL
Semaglutide 2.4 mg96482412
Semaglutide HD 7.2 mg288 **144 **7236
Liraglutide (daily) 3 mg120 **603015
Tirzepatide 5 mg200 **1005025
Tirzepatide 10 mg400 **200 **10050
Tirzepatide 15 mg600 **300 **150 **75
Retatrutide 4 mg160 **804020
Retatrutide 12 mg480 **240 **120 **60
Mazdutide 6 mg240 **120 **6030
Survodutide 3.6 mg144 **723618

** More than one 100-unit (1 mL) syringe. Branded pens (Wegovy, Zepbound, Saxenda) are dialled or fixed in mg and need no units; this table is for vials.

What the chart does not tell you

Detailed charts in units: semaglutide, tirzepatide, retatrutide, and microdosing semaglutide.

Drug-specific water guides: how much BAC water for tirzepatide and for 10 mg retatrutide.

Prefer a pill? Orforglipron (Foundayo) is a once-daily GLP-1 tablet with no injections and no fasting rules. Our orforglipron dosage chart lists all six tablet strengths, the step-up schedule and how trial doses such as 36 mg convert to today’s tablets.

Sources

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989–1002.
  2. HCPLive. FDA approves higher dose semaglutide (Wegovy HD) injection 7.2 mg for obesity (March 19, 2026).
  3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205–216; dosing: Drugs.com tirzepatide monograph.
  4. Drugs.com. Saxenda (liraglutide) prescribing information; SCALE trial, N Engl J Med 2015.
  5. Eli Lilly via BioSpace. Retatrutide TRIUMPH-1 Phase 3 results (May 21, 2026).
  6. Ji L, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1). N Engl J Med 2025.
  7. SYNCHRONIZE-1 (survodutide), ACC journal scan (June 2026).
  8. Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med 2025.